ADALIMUMAB

adalimumab 80 mg/0.8 mL injection, 0.8 mL pen device

ADALIMUMAB (12449F)

adalimumab 80 mg/0.8 mL injection, 0.8 mL pen device
12449F
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years), or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 2 Max qty units: 2 # of repeats: 2 DPMQ: $1,346.38 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Humira
Hyrimoz
Yuflyma